1) Georgios Georgiadis, Ioannis-Erineos Zisis, Anca Oana Docea, Konstantinos Tsarouhas, Irene Fragkiadoulaki, Charalampos Mavridis, Markos Karavitakis, Stavros Stratakis, Kostas Stylianou, Christina Tsitsimpikou, Daniela Calina, Nikolaos Sofikitis, Aristidis Tsatsakis and Charalampos Mamoulakis. Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review. Journal of Clinical Medicine epub ahead of print

2) Karavitakis M, Kyriazis I, Omar MI, Gravas S, Cornu JN, Drake MJ, Gacci M, Gratzke C, Herrmann TRW, Madersbacher S, Rieken M, Speakman MJ, Tikkinen KAO, Yuan Y, Mamoulakis C.Management of urinary retention in patients with benign prostatic obstruction: a systematic review and meta-analysis Eur Urol Feb 2019 epub ahead of print

3) Sakalis VI, Karavitakis M, Bedretdinova D, Bach T, Bosch JLHR, Gacci M, Gratzke C, Herrmann TR, Madersbacher S, Mamoulakis C, Tikkinen KAO, Gravas S, Drake MJ. Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. Eur Urol. 2017 Nov;72(5):757-769

4) M. Karavitakis, P. Msaouel, V. Michalopoulos, M. Koutsilieris. Pattern of somatostatin receptors expression in normal and bladder cancer tissue samples. Anticancer Research . 2014 Jun;34(6):2937-42

5) C. Komninos, M. Karavitakis, S. Koritsiadis. Fournier’s gangrene in a patient with obesity and B-lymphoma. Prague Med Rep 2013;114(3):186-90

6) M. Karavitakis, H.U Ahmed, P.D. Abel, S. Hazell, M.H. Winkler. Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy Ther Adv Urol. 2012 Aug;4(4):155-60.

7) M. Karavitakis, H.U Ahmed, P.D. Abel, S. Hazell, M.H. Winkler. Increasing use of active surveillance in the UK: trends in pathologic outcomes and implication for focal therapy Prostate. 2012 Sep 15;72(13):1464-8

8) M. Karavitakis, H.U Ahmed, P.D. Abel, S. Hazell, M.H. Winkler. Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer J Endourol. 2012 May;26(5):503-8.

9) M. Karavitakis, H.U Ahmed, P.D. Abel, S. Hazell, M.H. Winkler. Focal prostate therapy: opportunities and uncertainties. Discovery Journal 2011 Sep;12(64):245-55.

10) M.Karavitakis, C. Komninos, P. Theodorakis, V Politis, G. Lefakis, K Mitsios, S. Koritsiadis, G. Doumanis. Evaluation of sexual function in hypertensive men receiving treatment: a review of current guidelines recommendation . Journal of Sexual Medicine 2011 Sep;8(9):2405-14

11) Kontos S., Papatsoris A., Kominea A, Melachrinou M., Tanoglidi A., Kachrilas S., Karavitakis M., Balampani E., Sotiropoulou-Bonikou G. Expression of ERβ and its Co-Regulators p300 and NCoR in Human Transitional Cell Bladder Cancer. Urol Int 2011;87(2):151-8

12) M. Karavitakis, H.U Ahmed, P.D. Abel, S. Hazell, M.H. Winkler. Tumor focality in prostate cancer: implications for focal therapy. Nature Reviews Clinical Oncology 2011 Jan;8(1):48-55

13) M. Karavitakis, C. Komninos, V. Simaioforidis, S. Kontos, G. Lefakis, V. Politis, G. Koritsiadis, K. Konstantellou, G. Doumanis.The relationship between androgens, regulators of collagen metabolism and Peyronie’s Disease: A case control study. Journal of Sexual Medicine 2010 Dec;7(12):4011-7

14) M. Karavitakis, Winkler M, Abel P., Livni N., Beckley I., Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens:implications for focal therapy. Prostate Cancer and Prostatic Diseases 2011 Mar;14(1):46-52

15) S. Amir, M. tzatzarakis, C. Mamoulakis, JH Bello, S. Eqani, E. Vakonaki, M. Karavitakis, S. Sultan, F. tahir, S. Shah, A. Tsatsakis. Impact of organochlorine pollutants on semen parameters of infertile men in Pakistan. Environ Res . 2021 Apr;195:110832

16) M. Luna, M. Karavitakis. Letter to the editor: “Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver International. 2009. Oct;29(9):1448